AdvanCell Closes US$112M Series C Financing

AdvanCell, a Sydney, Australia-based clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, closed a US$112m Series C financing.

The round was co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis with participation from existing investor Morningside, alongside new investors Tenmile, Brandon Capital, and others. As part of the financing, Jamil M. Beg from SV Health Investors, Christopher Gagliardi from Sanofi Ventures, and Bali Muralidhar from Abingworth have joined the AdvanCell Board of Directors. They bring extensive industry expertise to support the company’s growth and join existing directors Bill Ferris AC, Anthony Aiudi, Kevin Cameron, and Andrew Adamovich.

The company intends to use the funds to advance ongoing efforts to expand its manufacturing capacity, accelerate the clinical development of its pipeline of radionuclide therapies, and advance its mission of delivering treatments to cancer patients worldwide.

Led by Andrew Adamovich, CEO, AdvanCell is dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By combining advanced manufacturing capabilities with cutting-edge science and clinical development capabilities, AdvanCell is currently enrolling patients for the highest dose cohort of its multi-center TheraPb Ph I/II dose escalation clinical trial of ADVC001 for metastatic prostate cancer, a potentially best-in-class Targeted Alpha Therapy. The trial aims to demonstrate the safety and efficacy of Pb-212-based radionuclide treatment.

FinSMEs

03/02/2025